+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Novel Vaccine Delivery Systems Market by Technology Approach, Administration Route, Formulation Composition, Patient Demographics, End User, Production Scale, Supply Chain, Distribution Channel, End Application - Global Forecast to 2030- Product Image
Novel Vaccine Delivery Systems Market by Technology Approach, Administration Route, Formulation Composition, Patient Demographics, End User, Production Scale, Supply Chain, Distribution Channel, End Application - Global Forecast to 2030- Product Image
Sale

Novel Vaccine Delivery Systems Market by Technology Approach, Administration Route, Formulation Composition, Patient Demographics, End User, Production Scale, Supply Chain, Distribution Channel, End Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6157828
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The advent of novel vaccine delivery systems heralds a new era in immunization, driven by advances in materials science, engineering and patient-centric design. Traditional needle-and-syringe methods have long dominated global vaccination efforts, yet they carry limitations related to cold chain dependency, biohazard waste and patient compliance. Over the past decade, breakthroughs such as microarray patches, nanoparticle carriers and needle-free injectors have captured the attention of developers and public health authorities alike. By enabling targeted delivery, dose sparing and improved thermostability, these platforms promise to enhance immune responses while reducing logistical burdens. As health systems grapple with emerging pathogens and endemic diseases, integrating these transformative approaches will be critical to expanding coverage and bolstering pandemic preparedness. This executive summary explores key trends, regulatory shifts and strategic imperatives shaping the landscape of vaccine delivery innovation, offering decision-makers a concise roadmap to navigate complex market dynamics and craft sustainable growth strategies.

Transformative Shifts in the Vaccine Delivery Landscape

The vaccine delivery landscape is undergoing transformative shifts driven by converging technological, regulatory and market forces. Electrically driven electroporation devices now promise precise intracellular antigen delivery, while microarray patches dissolve painlessly within minutes, obviating sharps waste. Nanoparticle delivery platforms-encompassing lipid nanoparticles that proved pivotal for mRNA vaccines and polymeric nanoparticles offering controlled release-are unlocking novel immunostimulatory profiles. Simultaneously, needle-free injection systems, including jet injectors and spring-actuated devices, are reducing phobia-related noncompliance and streamlining mass campaigns.

Regulatory agencies worldwide are accelerating approval pathways for these next-generation modalities, reflecting an emphasis on pandemic readiness and rapid technology transfer. At the same time, patient expectations around convenience and accessibility are reshaping clinical trial designs, driving a shift toward self-administrable formats and at-home vaccination models. Meanwhile, digital integration-from smart patch sensors to blockchain-enabled supply tracking-is fortifying traceability and real-time monitoring. Together, these shifts are redefining value propositions across public health programs, private clinics and research institutions, setting the stage for sustained adoption and cross-sector collaboration.

Cumulative Impact of U.S. Tariffs in 2025

In 2025, newly imposed tariffs by the United States on select bulk reagents, specialized manufacturing equipment and nanomaterials have reshaped cost structures across development pipelines. Manufacturers sourcing lipid excipients or polymer precursors now face levies that have driven a reevaluation of offshore versus domestic production strategies. To mitigate escalating input costs, some producers are forging joint ventures with local suppliers, while others are redesigning formulations to leverage tariff-exempt alternatives. Clinical research organizations have responded by consolidating reagent orders and negotiating framework agreements aimed at cost containment. Moreover, contract device fabricators are exploring lean production models that reduce reliance on imported capital goods.

These adjustments have rippled through distribution networks, prompting logistics providers to optimize shipment consolidation and explore cold chain independent options. Vaccine developers are balancing price adjustments with value-based contracting to preserve access in public health programs. As industry stakeholders adapt to this reshaped tariff environment, agility in procurement and strategic supplier partnerships have emerged as critical competitive differentiators.

Key Segmentation Insights

A multidimensional view of the market emerges when examining distinct segmentation lenses. Based on technology approach, the market is studied across electroporation, microarray patches that extend into dissolvable patches, nanoparticle delivery further categorized into lipid nanoparticles and polymeric nanoparticles, as well as needle-free injection subdivided into jet injectors and spring-actuated devices. When viewed through the administration route perspective, opportunities unfold across buccal delivery, inhalation delivery differentiated by dry powder inhalers and nebulizers, oral delivery and transdermal delivery platforms. From a formulation composition standpoint, adjuvanted formulations coexist alongside liquid and lyophilized formulations, while sustained release formulations leverage liposomal carriers and polymeric carriers.

Demographic targeting further refines strategic imperatives: adult and geriatric populations, pediatric cohorts, patients with chronic conditions and immunocompromised individuals each present unique tolerability and dosing requirements. End users span clinics, government programs, hospitals, pharmacies and research institutions, each demanding tailored stakeholder engagement and service models. Production scale considerations range from custom batch production to mass manufacturing and on-demand production workflows, influencing capital outlay and quality controls. Supply chain segmentation differentiates automated logistics, cold chain dependent networks and cold chain independent channels, affecting resilience and cost. Distribution channels include direct distribution agreements, hospital partnerships, online platforms and retail partnerships, each with distinct regulatory and commercial complexities. Finally, end applications cover emergency response, preventive vaccination and therapeutic vaccination, illuminating pathways for targeted innovation and value capture.

Key Regional Insights

Regional dynamics play a pivotal role in shaping adoption curves and investment priorities. In the Americas, robust biotechnology hubs and favorable funding environments have accelerated pilot programs for microarray patches and nanoparticle platforms, while established public health infrastructures are positioned to integrate needle-free injectors into mass immunization campaigns. Within Europe, the Middle East & Africa region, regulatory harmonization initiatives across the EU have streamlined approval processes, yet varying healthcare reimbursement models and infrastructure gaps in certain markets call for adaptive rollout strategies. Demand in the Middle East is buoyed by government vaccine mandates, and digital supply chain solutions are gaining traction across Africa to bridge cold chain limitations.

In Asia-Pacific, rapid expansion of manufacturing capacity-driven by technology transfer agreements and government incentives-has created a competitive landscape for lipid nanoparticle and polymeric nanoparticle production. Healthcare systems in markets such as Japan, South Korea and Australia are piloting self-administrable patches to increase adult booster uptake, while Southeast Asian nations are investing in inhalation delivery platforms to enhance pediatric immunization coverage. This regional mosaic underscores the need for tailored commercial frameworks and localized partnerships.

Key Company Insights

The competitive map is defined by legacy pharmaceutical giants, device specialists and agile startups. Leading vaccine players such as AstraZeneca PLC, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Moderna Therapeutics Inc., Novavax Inc., Pfizer Inc. and Sanofi S.A. are scaling in-house delivery innovations while forging alliances with specialist device manufacturers. Becton Dickinson and CapsuleTech Inc. are leveraging their device engineering expertise to co-develop next-generation injectors, while DermoVax Technologies, ImmunoPatch Systems and VaxiPatch Corp. are pioneering microarray patch applications.

Emerging innovators including Aria Vaccine Systems, BioDelivers LLC, InnoVax Inc., NanoVax Delivery Systems and NextGen Delivery Systems are disrupting formulation and manufacturing paradigms. Companies such as Cutis Pharma Solutions and SyringeFree Co. focus on needle-free injectors, and TransDerm Innovations Ltd., VaxInnovations Inc. and VaxiTech Solutions advance transdermal and sustained release carriers. ImmuRelease Corp., InhalNova Inc. and MediNano Innovations are enhancing inhalation and nanoparticle platforms. ProVax Devices and SI-BioSolutions Inc. are notable for custom production services, while research institutions and pharmacies partner to pilot direct distribution and online platforms. This diverse ecosystem underscores collaboration opportunities and the importance of differentiated value propositions.

Actionable Recommendations for Industry Leaders

Industry leaders should accelerate cross-disciplinary R&D by fostering partnerships between formulation scientists, device engineers and digital technology experts to achieve integrated delivery solutions. Diversifying supply chains through regional manufacturing hubs and tariff-free material sourcing agreements will mitigate cost pressures and ensure continuity. Embracing digital health tools-such as immunization tracking smart patches and AI-driven cold chain monitoring-will enhance real-time visibility and patient engagement.

Proactively engaging regulators through adaptive trial designs and real-world evidence studies can streamline approvals, while strategic alliances with public health agencies will facilitate large-scale rollouts. Investment in modular, on-demand production capabilities will support tailored batch sizes and rapid scale-up in emergency scenarios. Finally, developing value-based contracting models that link delivery performance to health outcomes will strengthen payer partnerships and drive adoption across diverse end users.

Conclusion

As the vaccine delivery space evolves, alignment of strategic priorities with technological capabilities will differentiate market leaders from followers. Stakeholders must integrate patient-centric design, regulatory foresight and supply chain resilience into their core strategies. Embracing collaboration across industry, academia and government will catalyze scalable solutions that address both endemic disease burdens and pandemic threats. Through targeted innovation, adaptive business models and data-driven execution, organizations can unlock the full potential of next-generation vaccine delivery systems.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology Approach
    • Electroporation
    • Microarray Patches
      • Dissolvable Patches
    • Nanoparticle Delivery
      • Lipid Nanoparticles
      • Polymeric Nanoparticles
    • Needle Free Injection
      • Jet Injectors
      • Spring Actuated Devices
  • Administration Route
    • Buccal Delivery
    • Inhalation Delivery
      • Dry Powder Inhalers
      • Nebulizers
    • Oral Delivery
    • Transdermal Delivery
  • Formulation Composition
    • Adjuvanted Formulation
    • Liquid Formulation
    • Lyophilized Formulation
    • Sustained Release Formulation
      • Liposomal Carriers
      • Polymeric Carriers
  • Patient Demographics
    • Adult
    • Chronic Conditions
    • Geriatric
    • Immunocompromised
    • Pediatric
  • End User
    • Clinics
    • Government Programs
    • Hospitals
    • Pharmacies
    • Research Institutions
  • Production Scale
    • Custom Production
    • Mass Production
    • On Demand Production
  • Supply Chain
    • Automated Logistics
    • Cold Chain Dependent
    • Cold Chain Independent
  • Distribution Channel
    • Direct Distribution
    • Hospital Partnerships
    • Online Platforms
    • Retail Partnerships
  • End Application
    • Emergency Response
    • Preventive Vaccination
    • Therapeutic Vaccination
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Aria Vaccine Systems
  • AstraZeneca PLC
  • Becton Dickinson
  • BioDelivers LLC
  • CapsuleTech Inc.
  • Cutis Pharma Solutions
  • DermoVax Technologies
  • GlaxoSmithKline
  • ImmunoPatch Systems
  • ImmuRelease Corp.
  • InhalNova Inc.
  • InnoVax Inc.
  • Johnson & Johnson
  • MediNano Innovations
  • Merck & Co.
  • Moderna Therapeutics Inc.
  • NanoVax Delivery Systems
  • NextGen Delivery Systems
  • Novavax Inc.
  • Pfizer Inc.
  • PharmaInnovate Ltd.
  • ProVax Devices
  • Sanofi S.A.
  • SI-BioSolutions Inc.
  • SyringeFree Co.
  • TransDerm Innovations Ltd.
  • VaxInnovations Inc.
  • VaxiPatch Corp.
  • VaxiTech Solutions
  • VaxTrans Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Novel Vaccine Delivery Systems Market, by Technology Approach
8.1. Introduction
8.2. Electroporation
8.3. Microarray Patches
8.3.1. Dissolvable Patches
8.4. Nanoparticle Delivery
8.4.1. Lipid Nanoparticles
8.4.2. Polymeric Nanoparticles
8.5. Needle Free Injection
8.5.1. Jet Injectors
8.5.2. Spring Actuated Devices
9. Novel Vaccine Delivery Systems Market, by Administration Route
9.1. Introduction
9.2. Buccal Delivery
9.3. Inhalation Delivery
9.3.1. Dry Powder Inhalers
9.3.2. Nebulizers
9.4. Oral Delivery
9.5. Transdermal Delivery
10. Novel Vaccine Delivery Systems Market, by Formulation Composition
10.1. Introduction
10.2. Adjuvanted Formulation
10.3. Liquid Formulation
10.4. Lyophilized Formulation
10.5. Sustained Release Formulation
10.5.1. Liposomal Carriers
10.5.2. Polymeric Carriers
11. Novel Vaccine Delivery Systems Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.3. Chronic Conditions
11.4. Geriatric
11.5. Immunocompromised
11.6. Pediatric
12. Novel Vaccine Delivery Systems Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Government Programs
12.4. Hospitals
12.5. Pharmacies
12.6. Research Institutions
13. Novel Vaccine Delivery Systems Market, by Production Scale
13.1. Introduction
13.2. Custom Production
13.3. Mass Production
13.4. On Demand Production
14. Novel Vaccine Delivery Systems Market, by Supply Chain
14.1. Introduction
14.2. Automated Logistics
14.3. Cold Chain Dependent
14.4. Cold Chain Independent
15. Novel Vaccine Delivery Systems Market, by Distribution Channel
15.1. Introduction
15.2. Direct Distribution
15.3. Hospital Partnerships
15.4. Online Platforms
15.5. Retail Partnerships
16. Novel Vaccine Delivery Systems Market, by End Application
16.1. Introduction
16.2. Emergency Response
16.3. Preventive Vaccination
16.4. Therapeutic Vaccination
17. Americas Novel Vaccine Delivery Systems Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Novel Vaccine Delivery Systems Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Novel Vaccine Delivery Systems Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Aria Vaccine Systems
20.3.2. AstraZeneca PLC
20.3.3. Becton Dickinson
20.3.4. BioDelivers LLC
20.3.5. CapsuleTech Inc.
20.3.6. Cutis Pharma Solutions
20.3.7. DermoVax Technologies
20.3.8. GlaxoSmithKline
20.3.9. ImmunoPatch Systems
20.3.10. ImmuRelease Corp.
20.3.11. InhalNova Inc.
20.3.12. InnoVax Inc.
20.3.13. Johnson & Johnson
20.3.14. MediNano Innovations
20.3.15. Merck & Co.
20.3.16. Moderna Therapeutics Inc.
20.3.17. NanoVax Delivery Systems
20.3.18. NextGen Delivery Systems
20.3.19. Novavax Inc.
20.3.20. Pfizer Inc.
20.3.21. PharmaInnovate Ltd.
20.3.22. ProVax Devices
20.3.23. Sanofi S.A.
20.3.24. SI-BioSolutions Inc.
20.3.25. SyringeFree Co.
20.3.26. TransDerm Innovations Ltd.
20.3.27. VaxInnovations Inc.
20.3.28. VaxiPatch Corp.
20.3.29. VaxiTech Solutions
20.3.30. VaxTrans Inc.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. NOVEL VACCINE DELIVERY SYSTEMS MARKET MULTI-CURRENCY
FIGURE 2. NOVEL VACCINE DELIVERY SYSTEMS MARKET MULTI-LANGUAGE
FIGURE 3. NOVEL VACCINE DELIVERY SYSTEMS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2024 VS 2030 (%)
FIGURE 20. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2024 VS 2030 (%)
FIGURE 24. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. NOVEL VACCINE DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. NOVEL VACCINE DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NOVEL VACCINE DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY JET INJECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SPRING ACTUATED DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY BUCCAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ORAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADJUVANTED FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY CHRONIC CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY CUSTOM PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MASS PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ON DEMAND PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY AUTOMATED LOGISTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COLD CHAIN DEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COLD CHAIN INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PARTNERSHIPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PARTNERSHIPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY EMERGENCY RESPONSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PREVENTIVE VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY THERAPEUTIC VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 108. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 109. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 110. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 111. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 112. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 113. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 114. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 115. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 116. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 118. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 119. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. CANADA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 122. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 123. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 125. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 127. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 128. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 129. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 133. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. MEXICO NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 180. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 181. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 182. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 183. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 184. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 185. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 186. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 187. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 188. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 190. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 191. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. CHINA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 194. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 195. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 196. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 197. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 198. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 199. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 200. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 201. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 202. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 204. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 205. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. INDIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 222. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 223. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 224. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 225. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 226. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 227. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 228. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 229. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 230. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 232. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 233. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. JAPAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NEEDLE FREE INJECTION, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY INHALATION DELIVERY, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY FORMULATION COMPOSITION, 2018-2030 (USD MILLION)
TABLE 284. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUSTAINED RELEASE FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 286. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 288. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY SUPPLY CHAIN, 2018-2030 (USD MILLION)
TABLE 289. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY END APPLICATION, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY APPROACH, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY MICROARRAY PATCHES, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN NOVEL VACCINE DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Novel Vaccine Delivery Systems market report include:
  • Aria Vaccine Systems
  • AstraZeneca PLC
  • Becton Dickinson
  • BioDelivers LLC
  • CapsuleTech Inc.
  • Cutis Pharma Solutions
  • DermoVax Technologies
  • GlaxoSmithKline
  • ImmunoPatch Systems
  • ImmuRelease Corp.
  • InhalNova Inc.
  • InnoVax Inc.
  • Johnson & Johnson
  • MediNano Innovations
  • Merck & Co.
  • Moderna Therapeutics Inc.
  • NanoVax Delivery Systems
  • NextGen Delivery Systems
  • Novavax Inc.
  • Pfizer Inc.
  • PharmaInnovate Ltd.
  • ProVax Devices
  • Sanofi S.A.
  • SI-BioSolutions Inc.
  • SyringeFree Co.
  • TransDerm Innovations Ltd.
  • VaxInnovations Inc.
  • VaxiPatch Corp.
  • VaxiTech Solutions
  • VaxTrans Inc.

Related Topics

Related Reports

Vaccine Adjuvants Market by Delivery Route (Intramuscular, Intranasal, Oral), Formulation (Emulsions, ISCOMs, Liposomes), End User, Vaccine Category - Global Forecast 2025-2030 - Product Image

Vaccine Adjuvants Market by Delivery Route (Intramuscular, Intranasal, Oral), Formulation (Emulsions, ISCOMs, Liposomes), End User, Vaccine Category - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Nanomaterial-Based Adjuvants Vaccine Market by Vaccine Formulation (Conjugate, DNA, mRNA), Nanomaterial Type (Inorganic Nanoparticles, Lipid Nanoparticles, Polymer Nanoparticles), Application, Route of Administration, End User - Global Forecast 2025-2030 - Product Image

Nanomaterial-Based Adjuvants Vaccine Market by Vaccine Formulation (Conjugate, DNA, mRNA), Nanomaterial Type (Inorganic Nanoparticles, Lipid Nanoparticles, Polymer Nanoparticles), Application, Route of Administration, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Vaccine Delivery Devices Market by Device Type (Auto-Injectors, Infusion Pumps, Jet Injectors), Administration Route (Intradermal Injection, Intramuscular Injection, Intravenous Injection), End User, Product Form - Global Forecast 2025-2030 - Product Image

Vaccine Delivery Devices Market by Device Type (Auto-Injectors, Infusion Pumps, Jet Injectors), Administration Route (Intradermal Injection, Intramuscular Injection, Intravenous Injection), End User, Product Form - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
DNA Vaccine Market by Application (Infectious Diseases, Oncology), Technology Platform (Linear DNA, Minicircle DNA, Plasmid DNA), Delivery Method, Administration Route, Development Stage, End User - Global Forecast 2025-2030 - Product Image

DNA Vaccine Market by Application (Infectious Diseases, Oncology), Technology Platform (Linear DNA, Minicircle DNA, Plasmid DNA), Delivery Method, Administration Route, Development Stage, End User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Therapeutic Vaccines Market by Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Technology Platform (Dendritic Cell, DNA, Peptide), Administration Route, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Therapeutic Vaccines Market by Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Technology Platform (Dendritic Cell, DNA, Peptide), Administration Route, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.